compani data secur llc estim reuter
non-gaap ep exclud stock-bas compens reflect adjust
compani prioriti stock list
compani data secur llc estim reuter
reiter outperform rate share gilead
scienc follow review result outlook
believ product trend assumpt support trough earn
return growth see upsid potenti
continu hiv product growth new growth driver includ cell
therapi nash immunolog
report result yesterday market close
provid outlook financi guidanc overal result
better expect non-gaap ep vs
consensu total revenu vs consensu
guidanc appear gener line consensu net
product sale vs consensu
expens guidanc suggest in-lin non-gaap ep rang
consensu non-gaap ep estim
focu potenti trough earn year
suggest slower predict declin hcv product sale
off-set continu strong hiv product growth
hcv product sale guidanc expect
stabl price market share expect stabil mid-year
slower predict declin new patient start
hiv/hbv product sale
increas expect
driven primarili continu strong growth genvoya new
product launch bic-ftc-taf follow expect approv feb
share taf base regimen expect
continu growth new patient start competitor switch
margin growth legaci atripla truvada switch
new product opportun highlight potenti growth
driver beyond includ cell therapi cancer led
car-t therapeut yescarta select jak inhibitor filgotinib
immunolog three differ pipelin asset non-alcohol
steatohepat nash led inhibitor selonsertib
follow inhibitor fxr inhibitor
yescarta launch focus site certif site
repres patient expect certifi
focu filgotinib develop on-going phase studi
rheumatoid arthriti ra ulcer coliti uc crohn
diseas initi ra data addit phase
studi support expand opportun initi focu nash
develop stellar studi selonsertib
data expect earli follow prior data
continu page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
final term capit alloc strateg initi support continu growth suggest
balanc approach increas quarterli dividend repurchas
share invest well partnership focus new product opportun
detail provid potenti deal suggest addit cell therapi technolog
consid improv prospect solid tumor includ gene edit capabl
hcv global sale yoy sequenti us hcv sale
yoy sequenti sequenti decreas driven mainli impact
increas competit eu hcv sale yoy sequenti
sequenti declin driven mainli increas competit partial off-set wider access certain
market intern market hcv sale yoy
sequenti number new patient start sequenti
eu flat sequenti japan sequenti
note four variabl drive hcv market patient start net price market share
treatment durat note treatment durat stabil price across
regimen gravit toward week regimen expect price market share
stabil predict slightli declin new patient start move forward
expect new patient start midpoint
sequenti sequenti japan
hiv hbv product global sale yoy sequenti primarili
driven higher demand taf-bas regimen global sale taf-bas regimen genvoya
odefsey descovi yoy sequenti taf-bas
regimen account gild prescript volum vs taf-bas regimen
continu prescrib hiv regimen across treatment nave switch patient
 across genvoya also repres success hiv launch first
hiv product reach annual sale truvada continu growth driver approxim
peopl take truvada prep pre-exposur prophylaxi expect approv
bictegravir/ftc/taf fix dose combin soon fda action date februari expect
regimen anoth posit momentum go forward overal see hiv franchis
 hiv market dynam describ million patient infect
diagnos patient antiretrovir treatment includ regimen
regard commerci launch newli approv adopt cellular therapi yescarta note
certifi cancer center date activ work train certifi addit
center expect certifi enough center treat yescarta-elig
sequenti changeyear/year except per share data hcv compani report factset secur llc estimatesconsensusgild first inc
note gild revenu guidanc vs actual anticip
increas hiv/hbv sale compar off-set decreas
hcv sale compar decreas due ex-u tdf patent expiri anoth
decreas due letairi patent expiri
guidanc hcv revenu vs actual anticip decreas
due total patient start anoth due competit environ
report result yesterday close compani report total revenu
billion vs billion consensu year-over-year quarter-over-
quarter billion revenu compris billion product sale million royalti
contract revenu compar billion product sale million
royalti contract revenu year-ago period non-gaap ep vs
consensu
term expens gross margin vs non-gaap expens
non-gaap sg expens
year-ago period compani non-gaap oper margin quarter compar
compani held cash cash equival decemb vs
end
guidanc
introduc full-year guidanc product sale guidanc project rang
billion non-gaap gross margin guidanc non-gaap expens guidanc
forecast rang billion non-gaap sg expens guidanc rang
billion guidanc non-gaap effect tax rate impact non-gaap
adjust expect rang
adjust financi model
updat financi model follow yesterday result compani guidanc
forecast hcv franchis sale sale reflect
compani guidanc drop-off hcv sale rang hiv/hbv sale forecast
post compani reflect guidanc
increas rang non-gaap ep forecast
revenu base includ product sale slightli ahead compani guidanc
earn call manag note tax cut job act
fundament chang compani capit alloc prioriti enabl addit invest
busi includ follow acquisit kite pharma cell design lab emphas
intent maintain leadership posit cell therapi continu invest new technolog
hiv pdufa date gild daili singl tablet regimen bic/f/taf bic/f/taf
replac cobicistat-boost integras inhibitor elvitegravir use f/taf genvoya non-
boost integras inhibitor bictegravir bic/f/taf smallest daili singl tablet
regimen product offer market approv expect bic/f/taf help continu growth
hiv franchis note hiv treatment guidelin adopt genvoya within week product
approv continu research hiv mileston comment highlight
tlr agonist develop hiv cure complet cohort phase
long act inject hiv capsid inhibitor treatment-resist diseas ind file first
patient expect
expect start phase trial nucleosid revers transcriptas inhibitor
nrti prodrug emtriva bic/f/taf nrti approv hiv prevent
descovi complet phase prep hiv prevent trial
non-alcohol steatohepat nash complet enrol stellar phase trial
apoptosi signal regul kinas selonsertib patient cirrhosi next
month expect complet enrol stellar phase trial selonsertib nash patient
bridg fibrosi expect data trial posit compani intend
file regulatori approv
stellar placebo-control trial selonsertib week nash patient
compens cirrhosi primari endpoint point greater decreas fibrosi score
week event free surviv week
stellar placebo-control trial selonsertib week nash patient
bridg fibrosi primari endpoint point greater decreas fibrosi score
without worsen nash week event free surviv week
also complet enrol trial selonsertib alcohol hepat evalu selonsertib
plu prednison versu prednison day addit conduct phase trial combin
selonsertib fxr-agonist inhibitor nash data expect
respect data studi expect present european associ
studi liver easl take place april pari fr intend initi larger
phase combin trial selonsertib later
gild specif inhibitor filgotinib evalu phase trial rheumatoid arthriti
crohn diseas ulcer coliti uc finch trial filgotinib ra patient
inadequ respons biolog diseas modifi anti-rheumat drug dmard complet
enrol top-lin data expect expect larger finch finch trial
complet enrol year select trial uc phase design interim analysi
futil expect occur
finch conduct adult moder sever diseas inadequ
respons methotrex trial compar one two dose level filgotinib
dose daili versu humira placebo dose trial doubl blind doubl
dummi design primari endpoint week trial durat month data
expect patient option continu blind fashion finch extens
trial addit month
finch conduct adult moder sever diseas inadequ
respons biolog dmard trial compar one two dose level filgotinib dose daili
versu placebo dose convent non-biolog dmard trial doubl blind doubl
dummi design primari endpoint week trial durat month data
expect patient option continu blind fashion finch extens
trial addit month
finch conduct adult moder sever diseas limit
prior treatment methotrex trial compar one two dose level filgotinib dose daili
versu trial doubl blind doubl dummi design primari endpoint
week trial durat month data expect patient option
continu blind fashion finch extens trial addit month
finch random blind placebo control trial one two dose filgotinib year
patient complet finch elig primari endpoint safeti
divers random blind placebo control doubl dummi phase trial one two dose
filgotinib week patient demonstr inadequ respons lost respons
intoler least follow agent steroid immunomodul tnf inhibitor
entyvio takeda intraven administ integrin receptor antagonist subject
random one two daili dose oral filgotinib placebo doubl blind doubl dummi
fashion subject meet response/complet respons criteria end induct
week continu mainten phase receiv filgotinib placebo week
select phase trial filgotinib ulcer coliti uc like divers trial evalu
one dose filgotinib placebo week induct follow mainten elig
subject moder sever diseas demonstr inadequ respons
lost respons intoler least follow agent steroid immunomodul
tnf inhibitor entyvio
also conduct proof concept phase trial filgotinib includ psoriat arthriti data
expect ankylos spondyl data expect addit monotherapi filgotinib
trial explor filgotinib combin inhibitor monotherapi
combin phase lupu data expect along btk inhibitor tirabutinib also
test combin filgotinib set sjogren syndrom data expect
earn call note compani file ind small molecul novel mechan
action target inflamm
gild andecaliximab antibodi inhibitor matrix metalloproteinas pass futil analysi
conduct data safeti monitor committe on-going front line gastric cancer trial
evalu folfox chemotherapi without andecaliximab per trial clinicaltri gov list
final data expect separ expect complet phase trial opdivo
andecaliximab gastric cancer patient
relapsed/refractori diffus larg cell lymphoma trial yescarta versu platinum-bas salvag
chemotherapi follow autolog stem cell transplant event free surviv primari endpoint
data expect also expand trial yescarta plu tecentriq
dlbcl near-term mileston expect includ
eu approv dlbcl
initi pivot phase trial relapsed/refractori indol lymphoma
initi pivot phase phase trial relapsed/refractori adult acut
complet phase pivot trial relapsed/refractori mantel cell lymphoma
initi pivot phase phase trial relapsed/refractori pediatr acut
initi phase trial chronic lymphocyt leukemia cll
move cell matur antigen target car-t multipl myeloma current
phase dose escal expect abl decid initi registr trial
engin cell receptor product target mage expect complet
phase dose escal portion trial intend file ind
etcr product human papilloma cancer
final expect data phase tirabutinib trial relapsed/refractori cll
price target nc
arriv price target appli multipl ep estim risk
includ continu slow hcv patient volum emerg credibl competit threat merck
particular failur key pipelin program hbv nash failur secur meaning revenu
opportun
expect stabil hcv trend visibl trough earn offset growth hiv product
emerg pipelin focus cell therapi cancer immunolog nash support out-performance
larg cap global commercial-stag biotechnolog compani discov develop small
molecul biolog drug global leadership hiv hcv expand beyond infecti
diseas liver diseas oncolog inflammation/fibrot diseas
